Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday a collaboration with precision medicine company Tempus AI Inc (NASDAQ:TEM) to accelerate the development of its selective AXL kinase inhibitor, bemcentinib, in first-line non-small cell lung cancer (NSCLC) patients with STK11 mutations.
This partnership will provide BerGenBio access to Tempus' real-world clinical and molecular data to enhance its ongoing Phase 1b/2a BGBC016 trial. Tempus' AI-enabled platform will provide insights into the genomic landscape and treatment responses of NSCLC patients with STK11 mutations.
Upon completion of the BGBC016 study, the companies plan to present insights derived from the resulting data to regulatory agencies.
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Summit Therapeutics and Pfizer partner to evaluate ivonescimab with ADCs in solid tumor trials
OS Therapies secures US patent for OST-HER2 manufacturing, extending exclusivity to 2040
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Kexing Biopharm's GB05 IND application receives US FDA approval
AroCell secures Chinese patent for respiratory infection detection
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline